Monographie - Cefepime dihydrochloride

Ultimele actualizari :
18/04/2024

Cefepime dihydrochloride

Formula chimica

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aspime	Venezuela
Avipim	Turcia
Axépim	Franta
Baxypime	Mexic
Cachepime	India
Cefalospim	Brazilia
Cefemin	Columbia
Cefepem	Brazilia
Cefepitax	Brazilia
Cepim	Italia
Cepimex	Italia
Forcetex	Egipt
Maxcef	Brazilia
Maxipime	Austria, Belgia, Canada, Columbia, Finlanda, Germania, Grecia, Italia, Luxemburg, Peru, Polonia, Portugalia, Spania, SUA, Suedia, Turcia, Ungaria
Nebamix	Peru
Olpelinol	Mexic
Pimcef	Peru
Pimerzen	Mexic
Roxipime	Turcia
Unisef	Turcia
Vipefime	Mexic

Bibliografie : Cefepime dihydrochloride

	Tip	Publicare
182	Ziar	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
251	Ziar	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873	Ziar	Das Gupta V, Maswoswe J, Bailey RE. Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound 1997 ; 1: 435-436.
921	Ziar	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1046	Ziar	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride in polypropylene syringes. Am J Health-Syst Pharm 1999 ; 56: 1134.
1068	Ziar	Stewart JT, Warren FW, Maddox FC. Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C. Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290	Ziar	Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM. Stability of cefepime in peritoneal dialysis solution. Ann Pharmacotherapy 1999 ; 33: 906-909.
1410	Ziar	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1605	Ziar	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C. Hosp Pharm 2000 ; 35: 1057-1064.
1625	Ziar	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1626	Ziar	Ling J, Das Gupta V. Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2001 ; 5: 151-152.
1648	Ziar	Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM. Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags. Int J Pharm Compound 2002 ; 6: 391-394.
1673	Ziar	Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC. Stability study of cefepime in different infusion solutions. Int J Pharm 1997 ; 154: 185-190.
1712	Ziar	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Ziar	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Ziar	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Ziar	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Ziar	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834	Ziar	Trissel LA, Xu QA. Stability of cefepime hydrochloride in autodose infusion system bags. Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945	Ziar	Elwell RJ, Volino LR, Frye RF. Stability of cefepime in icodextrin peritoneal dialysis solution. Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982	Ziar	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042	Ziar	Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046	Ziar	Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134	Ziar	Fubara JO, Notari RE. Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions. J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141	Ziar	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2192	Ziar	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231	Ziar	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Ziar	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254	Ziar	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385	Ziar	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416	Ziar	Csaba M, Boddu,S.H.S , Churchwell M.D. Physical compatibility of sodium citrate with alcohol and cefepime. Am J Health-Syst Pharm 2013 ; 70: 932-937
3520	Laborator	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3542	Ziar	Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion Am J Health-Syst Pharm 2015 ; 72:390-395
3548	Laborator	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3549	Laborator	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laborator	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laborator	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Ziar	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Ziar	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4055	Ziar	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Ziar	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Ziar	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326	Ziar	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.
4411	Ziar	Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Int J Pharm Compound 2020 ;24,3:238-241.
4434	Ziar	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Ziar	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4465	Ziar	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521	Ziar	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Ziar	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Ziar	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458

Mentions Légales